349
Participants
Start Date
May 14, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
March 1, 2026
ROSE (presence of cytotech) & liquid prep
Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
NO-ROSE (absence of cytotech) & liquid prep
Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is liquid.
ROSE (presence of cytotech) & tissue clot sample
Standard of care EBUS will include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
NO-ROSE (absence of cytotech) & tissue clot sample
Standard of care EBUS will NOT include presence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist during the procedure. Sample is a tissue clot.
Johns Hopkins Bayview Medical Center, Baltimore
Johns Hopkins Hospital, Baltimore
The Medical University of South Carolina (MUSC), Charleston
Northwestern Medicine, Chicago
Collaborators (1)
AstraZeneca
INDUSTRY
Johns Hopkins University
OTHER